Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

(2021) Tina Cascone et al.   NATURE MEDICINE

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Role of MPR as an early signal for efficacy in neoadjuvant studies

(2020) Collin M. Blakely et al.   CLINICAL CANCER RESEARCH

First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.

(2020) Christian U. Blank et al.   JOURNAL OF CLINICAL ONCOLOGY

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

(2020) Roy S. Herbst et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

(2020) Catherine A Shu et al.   LANCET ONCOLOGY

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

(2020) Mariano Provencio et al.   LANCET ONCOLOGY

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

(2020) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1

(2019) Kellie N. Smith et al.   Journal for ImmunoTherapy of Cancer

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial

(2019) Florian Eichhorn et al.   BMC CANCER

The promise of neoadjuvant immunotherapy and surgery for cancer treatment

(2019) Jake S O'Donnell et al.   CLINICAL CANCER RESEARCH

Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.

(2019) Irene Reijers et al.   JOURNAL OF CLINICAL ONCOLOGY

Current status of immune checkpoint inhibition in early-stage NSCLC

(2019) J Vansteenkiste et al.   ANNALS OF ONCOLOGY

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study

(2019) Wen-Zhao Zhong et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

(2019) Rodabe N Amaria et al.   LANCET ONCOLOGY

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

(2019) Elisa A Rozeman et al.   LANCET ONCOLOGY

Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer

(2019) Jiajia Zhang et al.   CLINICAL CANCER RESEARCH

Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells

(2019) Jay Friedman et al.   CLINICAL CANCER RESEARCH

OA13.05 NADIM Study: Updated Clinical Research and Outcomes

(2019) M. Provencio et al.   Journal of Thoracic Oncology

P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

(2019) J. Heymach et al.   Journal of Thoracic Oncology

P2.04-92 Neoadjuvant Durvalumab With or Without Sub-Ablative Stereotactic Radiotherapy (SBRT) in Patients with Resectable NSCLC (NCT02904954)

(2019) N. Altorki et al.   Journal of Thoracic Oncology

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN)

(2019) Elizabeth Ahern et al.   Trials

Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)

(2018) T R Cottrell et al.   ANNALS OF ONCOLOGY

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors

(2018) Matthew J. Bott et al.   ANNALS OF THORACIC SURGERY

Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer

(2018) Chi-Fu Jeffrey Yang et al.   ANNALS OF THORACIC SURGERY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

(2018) Patrick M. Forde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database

(2018) Matthew MacLean et al.   Oncotarget

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer

(2018) Tina Cascone et al.   CANCER RESEARCH

Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

(2018) Hiran C. Fernando et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiteurs du check-point immunitaire en néo-adjuvant dans les cancers bronchiques non à petites cellules localisés : essai IoNESCO

(2018) X. Mignard et al.   REVUE DES MALADIES RESPIRATOIRES

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Initial results of pulmonary resection following neoadjuvant nivolumab in patients with resectable non-small cell lung cancer

(2018) Matthew J. Bott et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma

(2018) Rodabe N. Amaria et al.   NATURE MEDICINE

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

(2018) Christian U. Blank et al.   NATURE MEDICINE

Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy

(2018) Jing Liu et al.   OncoImmunology

PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination

(2017) Arash Memarnejadian et al.   JOURNAL OF IMMUNOLOGY

P1.05-015 Major Pathological Response as a Predictive Value of Survival in Early-Stage NSCLC After Chemotherapy: Cohort of NATCH Phase III Trial

(2017) E. Carcereny et al.   Journal of Thoracic Oncology

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent

(2017) Alice O. Kamphorst et al.   SCIENCE

Current Trends of Lung Cancer Surgery and Demographic and Social Factors Related to Changes in the Trends of Lung Cancer Surgery: An Analysis of the National Database from 2010 to 2014

(2017) Samina Park et al.   Cancer Research and Treatment

Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC

(2017) Natasha K. Brockwell et al.   Cancer Immunology Research

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

(2017) Renato G. Martins et al.   Journal of the National Comprehensive Cancer Network

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition

(2016) Hélène Salmon et al.   IMMUNITY

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Treatment of Stage IIIA Non–Small-Cell Lung Cancer: A Concise Review for the Practicing Oncologist

(2016) Rafael Santana-Davila et al.   Journal of Oncology Practice

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies

(2015) Leisha A. Emens et al.   Cancer Immunology Research

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint

(2014) Matthew D Hellmann et al.   LANCET ONCOLOGY

The evolution of cancer surgery and future perspectives

(2014) Lynda Wyld et al.   Nature Reviews Clinical Oncology

Treatment of Stage I and II Non-small Cell Lung Cancer

(2013) John A. Howington et al.   CHEST

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)

(2013) Virginie Westeel et al.   EUROPEAN JOURNAL OF CANCER

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

(2012) Apar Pataer et al.   Journal of Thoracic Oncology

Recent trends in resection rates among non-small cell lung cancer patients in England

(2012) Sharma P Riaz et al.   THORAX

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

(2010) Enriqueta Felip et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation

(2010) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials

(2009) Eric Lim et al.   Journal of Thoracic Oncology

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

(2008) Gary M. Strauss et al.   JOURNAL OF CLINICAL ONCOLOGY